Adcock Ingram enjoyed a rise in sales but a dip in profit during its 2020/21 financial year, as the South African firm laid out plans to launch 20 products during its current financial year ending in June 2022, including 18 generics and one new chemical entity.

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.

Senior Beximco executive outlines details, including pricing nuances, of a deal with the Serum Institute of India for the supply to Bangladesh of the AstraZeneca/University of Oxford coronavirus vaccine. Will India’s neighbor also benefit from pricing adjustments?